• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

26.00 -0.06 (-0.23%)
Official Closing Price Updated: 7:00 PM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Arcus (RCUS) Q1 2026 Earnings Call Transcript ↗
May 05, 2026
Arcus (RCUS) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Arcus Biosciences (NYSE:RCUS) Q1 Loss Narrows But Revenues Miss Estimates; Focus Shifts to Kidney Cancer Drug Casdatifan ↗
May 05, 2026
Via Chartmill
News headline image
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
May 05, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
April 24, 2026
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Inc (NYSE:RCUS) Reports Mixed Q4 2025 Results as Pipeline Strategy Pivots to Casdatifan ↗
February 25, 2026
Via Chartmill
News headline image
Analyst Expectations For Arcus Biosciences's Future ↗
October 29, 2025
 
Via Benzinga
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ ↗
October 12, 2025
Via Stocktwits
News headline image
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
April 21, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
April 09, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
March 24, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
March 09, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
February 26, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
February 25, 2026
Arcus (RCUS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
February 25, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
February 23, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
February 11, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
January 26, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
January 07, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return ↗
January 05, 2026
Arcus Biosciences, a clinical-stage oncology innovator, reported significant insider selling as its stock capped a strong one-year return. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From Arcus Biosciences
Via Business Wire
News headline image
Why Did Arcus Biosciences Stock Slump 10% Today? ↗
December 12, 2025
Arcus will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival. 
Via Stocktwits
News headline image
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
December 12, 2025
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
December 09, 2025
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
November 18, 2025
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan ↗
November 02, 2025
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
October 30, 2025
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
October 30, 2025
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
October 28, 2025
From Arcus Biosciences
Via Business Wire
News headline image
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
October 19, 2025
From Arcus Biosciences
Via Business Wire
News headline image
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months ↗
October 13, 2025
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap